CorrespondenceHER2-low-positive breast cancer from four neoadjuvant clinical trials
References (5)
- et al.
HER2-low breast cancer: pathological and clinical landscape
J Clin Oncol
(2020) - et al.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Lancet Oncol
(2021)
There are more references available in the full text version of this article.
Cited by (2)
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022, Frontiers in Molecular Biosciences
© 2021 Elsevier Ltd. All rights reserved.